Ocular Therapeutix Inc (NASDAQ: OCUL)’s stock price has gone decline by -2.37 in comparison to its previous close of 8.78, however, the company has experienced a -13.59% decrease in its stock price over the last five trading days. zacks.com reported 2024-11-14 that Ocular Therapeutix (OCUL) came out with a quarterly loss of $0.26 per share versus the Zacks Consensus Estimate of a loss of $0.23. This compares to loss of $0.51 per share a year ago.
Is It Worth Investing in Ocular Therapeutix Inc (NASDAQ: OCUL) Right Now?
OCUL has 36-month beta value of 1.20. Analysts have mixed views on the stock, with 5 analysts rating it as a “buy,” 3 as “overweight,” 2 as “hold,” and 0 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for OCUL is 135.43M, and currently, short sellers hold a 9.36% ratio of that float. The average trading volume of OCUL on November 21, 2024 was 1.12M shares.
OCUL’s Market Performance
The stock of Ocular Therapeutix Inc (OCUL) has seen a -13.59% decrease in the past week, with a -21.07% drop in the past month, and a -5.91% fall in the past quarter. The volatility ratio for the week is 7.17%, and the volatility levels for the past 30 days are at 5.30% for OCUL. The simple moving average for the past 20 days is -16.64% for OCUL’s stock, with a 5.83% simple moving average for the past 200 days.
Analysts’ Opinion of OCUL
TD Cowen, on the other hand, stated in their research note that they expect to see OCUL reach a price target of $11, previously predicting the price at $7. The rating they have provided for OCUL stocks is “Buy” according to the report published on June 20th, 2024.
Piper Sandler gave a rating of “Overweight” to OCUL, setting the target price at $15 in the report published on May 31st of the current year.
OCUL Trading at -13.42% from the 50-Day Moving Average
After a stumble in the market that brought OCUL to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -27.20% of loss for the given period.
Volatility was left at 5.30%, however, over the last 30 days, the volatility rate increased by 7.17%, as shares sank -22.94% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -3.65% lower at present.
During the last 5 trading sessions, OCUL fell by -15.41%, which changed the moving average for the period of 200-days by +67.84% in comparison to the 20-day moving average, which settled at $10.27. In addition, Ocular Therapeutix Inc saw 92.20% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at OCUL starting from PHILIP C. STRASSBURGER, who proposed sale 13,125 shares at the price of $10.23 back on Oct 16 ’24. After this action, PHILIP C. STRASSBURGER now owns shares of Ocular Therapeutix Inc, valued at $134,269 using the latest closing price.
Nayak Sanjay, the Chief Strategy Officer of Ocular Therapeutix Inc, sale 1,832 shares at $9.02 during a trade that took place back on Aug 23 ’24, which means that Nayak Sanjay is holding 176,194 shares at $16,525 based on the most recent closing price.
Stock Fundamentals for OCUL
Current profitability levels for the company are sitting at:
- -2.3 for the present operating margin
- 0.91 for the gross margin
The net margin for Ocular Therapeutix Inc stands at -2.84. The total capital return value is set at -0.31. Equity return is now at value -96.89, with -53.42 for asset returns.
Based on Ocular Therapeutix Inc (OCUL), the company’s capital structure generated 0.16 points at debt to capital in total, while cash flow to debt ratio is standing at -1.62. The debt to equity ratio resting at 0.2. The interest coverage ratio of the stock is -9.66.
Currently, EBITDA for the company is -66.42 million with net debt to EBITDA at 2.26. When we switch over and look at the enterprise to sales, we see a ratio of 16.2. The receivables turnover for the company is 2.03for trailing twelve months and the total asset turnover is 0.13. The liquidity ratio also appears to be rather interesting for investors as it stands at 13.01.
Conclusion
To put it simply, Ocular Therapeutix Inc (OCUL) has had a mixed performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
